Pulmatrix - press releases http://ir.pulmatrix.com/ Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering http://ir.pulmatrix.com/2018-03-29-Pulmatrix-Announces-Pricing-Of-15-2-Million-Underwritten-Public-Offering Thu, 29 Mar 2018 00:02:00 -0400 http://ir.pulmatrix.com/2018-03-29-Pulmatrix-Announces-Pricing-Of-15-2-Million-Underwritten-Public-Offering Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline http://ir.pulmatrix.com/2018-03-13-Pulmatrix-Reports-2017-Financial-Results-Provides-2018-Outlook-on-Pulmonary-Disease-Pipeline Tue, 13 Mar 2018 16:43:00 -0400 http://ir.pulmatrix.com/2018-03-13-Pulmatrix-Reports-2017-Financial-Results-Provides-2018-Outlook-on-Pulmonary-Disease-Pipeline Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSEā„¢ Formulation of Itraconazole http://ir.pulmatrix.com/2018-02-12-Pulmatrix-Announces-First-Subject-Dosed-in-Phase-1-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Phase 1 data is expected in mid-2018 Mon, 12 Feb 2018 09:35:00 -0500 http://ir.pulmatrix.com/2018-02-12-Pulmatrix-Announces-First-Subject-Dosed-in-Phase-1-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018 http://ir.pulmatrix.com/2018-01-24-Pulmatrix-Will-Present-Pulmazole-Preclinical-Data-at-the-8th-Advances-Against-Aspergillosis-Conference-to-be-Held-February-1-3-2018 Wed, 24 Jan 2018 12:00:00 -0500 http://ir.pulmatrix.com/2018-01-24-Pulmatrix-Will-Present-Pulmazole-Preclinical-Data-at-the-8th-Advances-Against-Aspergillosis-Conference-to-be-Held-February-1-3-2018 Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSEā„¢ Formulation of Itraconazole http://ir.pulmatrix.com/2018-01-22-Pulmatrix-Announces-Acceptance-of-a-Clinical-Trial-Application-in-Europe-for-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Screening of subjects for this first-in-human study has begun and represents an important milestone in advancing this first in class therapy to the clinic Mon, 22 Jan 2018 10:25:00 -0500 http://ir.pulmatrix.com/2018-01-22-Pulmatrix-Announces-Acceptance-of-a-Clinical-Trial-Application-in-Europe-for-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole